MTOR and non-small cell lung carcinoma: Current genomic hallmarks for NSCLC include somatic mutations in PTPN11 (EGFR), SOS1 (KRAS), and STK11 (neutrophil degranulation) [6], and future therapeutic decisions will be helped by an increased understanding of other NSCLC-related pathways, such as EGFR, PI3K/AKT/mTOR, RAS/MAPK, and JAK/STAT [7].